571 related articles for article (PubMed ID: 30689697)
1. Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload.
Shi L; Zhu D; Wang S; Jiang A; Li F
Am J Hypertens; 2019 Apr; 32(5):452-459. PubMed ID: 30689697
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling.
Zhang Y; Lin X; Chu Y; Chen X; Du H; Zhang H; Xu C; Xie H; Ruan Q; Lin J; Liu J; Zeng J; Ma K; Chai D
Cardiovasc Diabetol; 2021 Jun; 20(1):121. PubMed ID: 34116674
[TBL] [Abstract][Full Text] [Related]
3. The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction.
Withaar C; Meems LMG; Markousis-Mavrogenis G; Boogerd CJ; Silljé HHW; Schouten EM; Dokter MM; Voors AA; Westenbrink BD; Lam CSP; de Boer RA
Cardiovasc Res; 2021 Jul; 117(9):2108-2124. PubMed ID: 32871009
[TBL] [Abstract][Full Text] [Related]
4. Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure.
Li X; Lu Q; Qiu Y; do Carmo JM; Wang Z; da Silva AA; Mouton A; Omoto ACM; Hall ME; Li J; Hall JE
J Am Heart Assoc; 2021 Mar; 10(6):e018298. PubMed ID: 33719499
[TBL] [Abstract][Full Text] [Related]
5. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
Ye Y; Bajaj M; Yang HC; Perez-Polo JR; Birnbaum Y
Cardiovasc Drugs Ther; 2017 Apr; 31(2):119-132. PubMed ID: 28447181
[TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
[TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction.
Zhang N; Feng B; Ma X; Sun K; Xu G; Zhou Y
Cardiovasc Diabetol; 2019 Aug; 18(1):107. PubMed ID: 31429767
[TBL] [Abstract][Full Text] [Related]
8. Alamandine improves cardiac remodeling induced by transverse aortic constriction in mice.
Silva MM; de Souza-Neto FP; Jesus ICG; Gonçalves GK; Santuchi MC; Sanches BL; de Alcântara-Leonídio TC; Melo MB; Vieira MAR; Guatimosim S; Santos RAS; da Silva RF
Am J Physiol Heart Circ Physiol; 2021 Jan; 320(1):H352-H363. PubMed ID: 33124885
[TBL] [Abstract][Full Text] [Related]
9. Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.
Chen H; Tran D; Yang HC; Nylander S; Birnbaum Y; Ye Y
Cardiovasc Drugs Ther; 2020 Aug; 34(4):443-461. PubMed ID: 32335797
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF-2α signaling pathway in arrhythmogenic cardiomyopathy.
Yang Z; Li T; Xian J; Chen J; Huang Y; Zhang Q; Lin X; Lu H; Lin Y
FASEB J; 2022 Jul; 36(7):e22410. PubMed ID: 35713937
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction.
Connelly KA; Zhang Y; Desjardins JF; Thai K; Gilbert RE
Cardiovasc Diabetol; 2018 Jul; 17(1):99. PubMed ID: 29981571
[TBL] [Abstract][Full Text] [Related]
12. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats.
Durak A; Olgar Y; Degirmenci S; Akkus E; Tuncay E; Turan B
Cardiovasc Diabetol; 2018 Nov; 17(1):144. PubMed ID: 30447687
[TBL] [Abstract][Full Text] [Related]
13. Protective effects of recombinant human erythropoietin against pressure overload-induced left ventricular remodeling and premature death in mice.
Wang W; Kagaya Y; Asaumi Y; Fukui S; Takeda M; Shimokawa H
Tohoku J Exp Med; 2011 Oct; 225(2):131-43. PubMed ID: 21937860
[TBL] [Abstract][Full Text] [Related]
14. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
Connelly KA; Zhang Y; Desjardins JF; Nghiem L; Visram A; Batchu SN; Yerra VG; Kabir G; Thai K; Advani A; Gilbert RE
Cardiovasc Diabetol; 2020 Feb; 19(1):13. PubMed ID: 32035482
[TBL] [Abstract][Full Text] [Related]
15. The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload.
Meems LM; Cannon MV; Mahmud H; Voors AA; van Gilst WH; Silljé HH; Ruifrok WP; de Boer RA
J Steroid Biochem Mol Biol; 2012 Nov; 132(3-5):282-9. PubMed ID: 22800987
[TBL] [Abstract][Full Text] [Related]
16. T₁ mapping detects pharmacological retardation of diffuse cardiac fibrosis in mouse pressure-overload hypertrophy.
Stuckey DJ; McSweeney SJ; Thin MZ; Habib J; Price AN; Fiedler LR; Gsell W; Prasad SK; Schneider MD
Circ Cardiovasc Imaging; 2014 Mar; 7(2):240-9. PubMed ID: 24425501
[TBL] [Abstract][Full Text] [Related]
17. A novel mtDNA repair fusion protein attenuates maladaptive remodeling and preserves cardiac function in heart failure.
Bradley JM; Li Z; Organ CL; Polhemus DJ; Otsuka H; Islam KN; Bhushan S; Gorodnya OM; Ruchko MV; Gillespie MN; Wilson GL; Lefer DJ
Am J Physiol Heart Circ Physiol; 2018 Feb; 314(2):H311-H321. PubMed ID: 29101177
[TBL] [Abstract][Full Text] [Related]
18. Experimental model of congestive heart failure induced by transverse aortic constriction in BALB/c mice.
Tannu S; Allocco J; Yarde M; Wong P; Ma X
J Pharmacol Toxicol Methods; 2020; 106():106935. PubMed ID: 33096237
[TBL] [Abstract][Full Text] [Related]
19. Empagliflozin prevents doxorubicin-induced myocardial dysfunction.
Sabatino J; De Rosa S; Tammè L; Iaconetti C; Sorrentino S; Polimeni A; Mignogna C; Amorosi A; Spaccarotella C; Yasuda M; Indolfi C
Cardiovasc Diabetol; 2020 May; 19(1):66. PubMed ID: 32414364
[TBL] [Abstract][Full Text] [Related]
20. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
Li C; Zhang J; Xue M; Li X; Han F; Liu X; Xu L; Lu Y; Cheng Y; Li T; Yu X; Sun B; Chen L
Cardiovasc Diabetol; 2019 Feb; 18(1):15. PubMed ID: 30710997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
